https://www.equinox-group.com/our-take-blog daily 0.75 2026-10-06 https://www.equinox-group.com/our-take-blog/zegfrovy-has-proven-itself-to-be-a-viable-alternative-to-rybrevant-chemotherapy-in-1l-egfr-exon-20-insertion-mutated-nsclc monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/d491af89-b5ba-4ddf-8656-018479a5a3a1/Rybrevant.png Our Insights - Zegfrovy Has Proven Itself to Be a Viable Alternative to Rybrevant + Chemotherapy in 1L EGFR EXON 20 Insertion-Mutated NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/83b68d39-a56c-4586-bfc0-5dd807fbc4b0/Zegfrovy+Figure+LinkedIn.png Our Insights - Zegfrovy Has Proven Itself to Be a Viable Alternative to Rybrevant + Chemotherapy in 1L EGFR EXON 20 Insertion-Mutated NSCLC - Make it stand out Figure 1: Drivers of Clinical Innovation for Rybrevant + chemotherapy and Zegfrovy when compared to chemotherapy alone https://www.equinox-group.com/our-take-blog/bms-gains-approval-for-first-ever-celmod-zenbexus-in-relapsedrefractory-multiple-myeloma-and-appears-poised-for-the-approval-of-one-more monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/598010f5-5e7f-4b1a-8090-48796636a0c4/MeziKd+Figure.png Our Insights - BMS gains approval for first ever CELMoD, Zenbexus, in relapsed/refractory multiple myeloma and appears poised for the approval of one more - Make it stand out Figure 1: Drivers of Clinical Innovation for MeziKd vs. KRd https://www.equinox-group.com/our-take-blog/cytokinetics-myqorzo-is-on-track-for-a-significant-label-expansion-into-nhcm-where-in-class-rival-camzyos-failed-payers-are-the-next-challenge monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/bdb46bdb-e6fc-4642-9e78-41a08615941d/Drivers+HCM+Linkedin.png Our Insights - Cytokinetics’ Myqorzo is On Track For a Significant Label Expansion into nHCM, Where In-Class Rival Camzyos Failed. Payers are the Next Challenge. - Make it stand out Figure 1: Drivers of Clinical Innovation for Camzyos and Myqorzo, Each Compared with Its Respective Control Arm https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/75b0d6fc-08b4-4d66-a74a-e122e47ab5bf/CB+HCM+Linkedin+Fix.png Our Insights - Cytokinetics’ Myqorzo is On Track For a Significant Label Expansion into nHCM, Where In-Class Rival Camzyos Failed. Payers are the Next Challenge. - Make it stand out Figure 2: Market Access in Obstructive and Non-Obstructive HCM https://www.equinox-group.com/our-take-blog/rigels-veppanu-scores-its-first-nod-in-her2-er-esr1-mutant-locally-advanced-or-metastatic-breast-cancer-making-it-the-first-protac-approved monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/82c0db20-959a-4187-abc2-c7a28854965b/unmet-need-drivers-comparison-v2+%281%29.png Our Insights - Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved - Make it stand out Figure 1: Drivers of Clinical Innovation for Each Protein Degrader, Each Compared with Its Respective Control Arm https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/d097114a-9f4a-40ec-853e-46a07d242a06/imlunestrant-vs-vepdegestrant-v2.png Our Insights - Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved - Make it stand out Figure 2: Drivers of Clinical Innovation, Veppanu vs. Inluriyo https://www.equinox-group.com/our-take-blog/lipfendra-brings-pcsk9i-efficacy-with-oral-convenience monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1ced34a8-b781-404c-b21b-1d6361ab18dd/PrimaryPrevBanner.png Our Insights - Lipfendra Brings PCSK9i Efficacy with Oral Convenience - Make it stand out Drivers chart depicting what Equinox believes Lipfendra may look like in the future compared to Repatha for primary prevention of MACE in high-risk patients. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/61d22969-e7ae-4f15-a581-4e8fc0c97ab7/SecondaryPrevBanner.png Our Insights - Lipfendra Brings PCSK9i Efficacy with Oral Convenience - Make it stand out Drivers chart depicting what Equinox believes Lipfendra may look like in the future compared to Repatha for secondary prevention of MACE https://www.equinox-group.com/our-take-blog/cogents-bezuclastinib-reduces-risk-of-disease-progression-or-death-by-50-in-2l-metastatic-gist-when-combined-with-standard-of-care monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/736379e1-c1a2-4e5f-97d5-49503e789ac5/bezuclastinib+%2B+sunitinib+base+case+Figure.png Our Insights - Cogent’s bezuclastinib reduces risk of disease progression or death by 50% in 2L metastatic GIST when combined with standard of care - Make it stand out Figure 1: Drivers of Clinical Innovation - Base Case https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/7e03df9e-027b-4a6c-bc9f-6744632c2f23/bezuclastinib+%2B+sunitinib+upside+case+Figure.png Our Insights - Cogent’s bezuclastinib reduces risk of disease progression or death by 50% in 2L metastatic GIST when combined with standard of care - Make it stand out Figure 2: Drivers of Clinical Innovation - Upside Case https://www.equinox-group.com/our-take-blog/trop2-adcs-a-major-innovation-for-1l-tnbc monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/d28b1f02-e9e8-4fe0-a83b-b1d79b45b4fc/Ind2+-+Chemo+%28TROP-2%29+vs+Datroway+Figure.png Our Insights - TROP2 ADCs: A Major Innovation for 1L TNBC - Make it stand out Figure 1: Drivers of Clinical Innovation – Datroway in 1L TNBC ineligible for IO https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/cd850ac6-0c97-4022-9d5f-c42b573eded4/Ind2+-+Chemo+%28ASC-3%29+vs+Trodelvy+Figure.png Our Insights - TROP2 ADCs: A Major Innovation for 1L TNBC - Make it stand out Figure 2: Drivers of Clinical Innovation – Trodelvy in 1L TNBC ineligible for IO https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1c69ba58-82e4-4235-923d-12a07edb11e0/Ind2+-+Trodelvy+vs+Datroway+Figure.png Our Insights - TROP2 ADCs: A Major Innovation for 1L TNBC - Make it stand out Figure 3: Drivers of Clinical Innovation – Datroway vs. Trodelvy in 1L TNBC ineligible for IO https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/0f2ca59f-39b5-4f40-9941-d0c5b7c49905/Ind1+-+Keytruda+%2B+Chemo+vs+Trodelvy+%2B+Keytruda+Figure.png Our Insights - TROP2 ADCs: A Major Innovation for 1L TNBC - Make it stand out Figure 4: Drivers of Clinical Innovation – Trodelvy in 1L TNBC, PD-L1-positive https://www.equinox-group.com/our-take-blog/tp53-the-most-altered-gene-in-oncology monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/6c1445da-fd5f-42ce-a327-e319c15830bb/TP53+Pathway+LinkedIn+HQ.jpg Our Insights - TP53, the most altered gene in oncology - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/lifyorli monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/5da2edf3-72ac-41dc-8fc1-d6563876fa93/Lifyorli-Figure+%283%29.jpg Our Insights - Lifyorli Approved in Platinum-Resistant Ovarian Cancer Thanks to a 35% Reduction in Mortality - Make it stand out Figure 1: Drivers of Clinical Benefit https://www.equinox-group.com/our-take-blog/dont-snooze-on-oveporexton-for-narcolepsy-type-1 monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/6149faaf-b931-4931-b1ab-48ac26fff3a6/oveporexton+Figure.jpg Our Insights - Oveporexton Could be a Game-changer for Narcolepsy Type 1 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/problem-with-pmr monthly 0.5 2026-09-24 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/32c7eb08-e98b-4589-b1d0-afbc90b33a33/Kisqali-at-launch.jpg Our Insights - The Problem with Primary Market Research - Make it stand out Figure 1: Kisqali at launch https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/f58b4214-c7f6-4953-9212-8a00b0ffcd02/Kisqali-OS-benefit.jpg Our Insights - The Problem with Primary Market Research - Make it stand out Figure 2: Kisqali update https://www.equinox-group.com/our-take-blog/gene-therapies-for-sickle-cell-disease-expensive-but-worth-it monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/e0b7dd52-08e1-4523-a8ff-18e5477ab3fb/Casgevy-Figure.jpg Our Insights - Gene Therapies for Sickle Cell Disease: Expensive but Worth It - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/keytruda-proc monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/5d88628e-a04a-4c2f-8cb2-044fc8d964d9/Keytruda-paclitaxel-bevacizumab-Figure.jpg Our Insights - Keytruda Grabs its 42nd Approval in PD-L1+ PROC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/handling-uncertainty monthly 0.5 2026-09-24 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/72550794-49d1-4f16-84ff-c66122768173/no+threat+%283%29.png Our Insights - Plan for the Best, Prepare for the Worst - Handling Uncertainty in R&D - Make it stand out Figure 1: Launching without a threat https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/e1244070-bc16-4a8e-802b-7fd35cf2cff9/no+threat+%281%29.png Our Insights - Plan for the Best, Prepare for the Worst - Handling Uncertainty in R&D - Make it stand out Figure 2: Launching with a threat https://www.equinox-group.com/our-take-blog/finding-opportunities monthly 0.5 2026-09-24 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/18543269-aab1-48ed-9f86-310a5f247f49/Factors+we+assess.png Our Insights - Finding the Best R&D Opportunities - Make it stand out Figure 1: Factors we assess https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/69b410d3-87ea-40b1-a232-04b99cc8fd2e/Indication+Prioritization+CompEnv+vs+UMN.png Our Insights - Finding the Best R&D Opportunities - Make it stand out Figure 2: Competitive intensity vs. unmet medical need https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/79f0c619-42c7-4f84-b3b3-b11a1b14d4f0/heat+map+for+website.png Our Insights - Finding the Best R&D Opportunities - Make it stand out Figure 3: An introduction to heat maps https://www.equinox-group.com/our-take-blog/drivers-charts monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/97f594fc-417d-4bc1-9b69-b1d787dfe84d/CI+PNH.PNG Our Insights - Using Equinox Drivers Charts to Understand Fabhalta's Success in PNH - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1d33853d-fd2e-4d50-8254-49cde523a207/Contributions+PNH.PNG Our Insights - Using Equinox Drivers Charts to Understand Fabhalta's Success in PNH - Make it stand out Soliris 2007 reflects Soliris WAC at launch; all costs inflated to 2025 USD. https://www.equinox-group.com/our-take-blog/measuring-risk-in-rd monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/0c64df89-8be6-4387-a4c9-8bf62391f167/market_matrix_table.jpg Our Insights - Measuring Risk in R&D - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://video.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/3e166ecc-4374-4fe1-bec5-d8dfeb2f0abb/playlist.m3u8 https://video.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/3e166ecc-4374-4fe1-bec5-d8dfeb2f0abb/thumbnail Our Insights - Measuring Risk in R&D Our Insights - Measuring Risk in R&D https://www.equinox-group.com/our-take-blog/alecensa-case-study monthly 0.5 2026-08-13 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/44d58614-a51e-453a-a99c-915fc50c0fe3/ACS_Picture1.png Our Insights - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/02619c8e-730e-485d-a1dd-940e7ac352e3/Screenshot+2025-11-17+085703.png Our Insights - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/be5fbfdd-19f8-487e-984b-075962480e7a/ACS_Picture3.png Our Insights - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/0cbad2ec-b55a-4afd-b7a9-0bf17d1be570/ACS_Picture4.png Our Insights - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/a09ce1d4-a144-4fc9-99e5-9e4d97ad0321/ACS_Picture5.png Our Insights - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/ad15e8d7-e46d-46c8-a2bd-9a4e1972d7c3/ACS_Picture6.png Our Insights - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/7bffd806-f88b-4f03-a0e0-b9cb998d9632/ACS_Picture7.png Our Insights - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/5045e5ca-da55-4924-924c-cdcce8c1e75d/ACS_Picture8.png Our Insights - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/ff55c377-5893-4eb3-ba8e-20fb3a724a36/ACS_Picture9.png Our Insights - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/8c955c20-b8c1-494a-854b-9c75a476d9ab/ACS_Picture10.png Our Insights - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/5ad4adca-787d-4a70-9649-9567cd0bea0b/ACS_Picture11.png Our Insights - How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/indication-prioritization monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/5c224d76-5740-41fb-b8a8-c9bdff07ca6c/Screenshot+2025-10-30+154345.png Our Insights - What indications should we focus on? - Make it stand out Figure 1: Clinical Innovation, Population Size, and Medical Need: A New Drug in 8 Indications https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/207ae8d1-ddc1-4086-b6b3-ff5c79a13d5a/Screenshot+2025-10-30+153908.png Our Insights - What indications should we focus on? - Make it stand out Figure 2: Clinical Innovation, Population Size, and Competitive Intensity: A New Drug in 8 Indications https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/17e50149-08dd-4afe-95f6-cb8ebc6efa0e/Screenshot+2025-10-30+164249.png Our Insights - What indications should we focus on? - Make it stand out Table 1: The Complete View *Undifferentiated from SOC https://www.equinox-group.com/our-take-blog/suzetrigine monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/619ff777-12dd-4997-9813-b723cb89b9c0/Suzetrigine+drivers.jpg Our Insights - Journavx, a vast improvement over opioids in moderate acute pain - Make it stand out Figure 1: Drivers of Journavx's Clinical Innovation https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/6cad09fd-edb2-494f-a56e-055ed2fe13fc/Screenshot+2025-09-12+142033.png Our Insights - Journavx, a vast improvement over opioids in moderate acute pain - Make it stand out Figure 2: Understanding Clinical Innovation https://www.equinox-group.com/our-take-blog/enhertu-first-line-her2 monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/dcec0eaf-7e48-46eb-8e1b-7d52ae9e73f0/Enhertu+regimen+Figure+%281%29.jpg Our Insights - Enhertu is poised to dominate first-line HER2+ breast cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/xolair monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/3b97aa0b-a104-4541-8e9c-4937ef90cf6a/Xolair-Figure+JPG.jpg Our Insights - Xolair for food allergies: effective therapy at a high price - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/monoclonal-antibodies-alzheimers monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/3679d700-56ca-4e97-a85f-e91955dbe2f7/Leqembi-Figure.jpg Our Insights - Monoclonal antibodies for Alzheimer’s disease: questionable clinical benefit at a high price - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/evrysdi-a-potential-game-changer-for-sma-type-1-patients monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/3b0a770e-8907-46db-b0cc-d8a44208a7ec/Evrysdi-figure.jpg Our Insights - Evrysdi: A Potential Game-Changer for SMA Type 1 Patients - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/03157b8e-b06a-4f19-8dcc-6724f2a8c340/quarterly+revenue+ppt+slide.jpg Our Insights - Evrysdi: A Potential Game-Changer for SMA Type 1 Patients - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/9d7147e7-a1a1-4105-b26a-a4ac613ee843/running+total+tx+cost.jpg Our Insights - Evrysdi: A Potential Game-Changer for SMA Type 1 Patients - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/car-t-outlook monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/6647ee5e-f9bc-4199-88fb-a2b0344cb3c7/Yescarta.png Our Insights - CAR-T Outlook - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/prospects-for-ulotaront-in-schizophrenia monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/f874e9f6-30f8-45a6-ad06-95ddd500558c/Risperidone-vs.-Ulatorant.jpg Our Insights - Prospects for ulotaront in schizophrenia - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/c81ea71a-8406-48ed-bc32-accb61c17113/Lybalvi-vs.-Ulotaront.jpg Our Insights - Prospects for ulotaront in schizophrenia - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/enhertu-a-highly-innovative-therapy-for-second-line-metastatic-breast-cancer monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/3e29f6cc-71bc-4c18-8492-6be7c7c15eb3/Enhertu-vs.-Kadcyla.jpg Our Insights - Enhertu shows high clinical innovation in second-line metastatic breast cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/49499deb-89f2-483d-82e6-7273e1caffe9/Enhertu-vs.-Halaven.jpg Our Insights - Enhertu shows high clinical innovation in second-line metastatic breast cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/weighing-efficacy-vs-tolerability-lenvima-keytruda-in-advanced-ccrcc monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/88a6309b-cff2-4cb3-95cb-edf95035b2e1/Keytruda-and-Lenvima-Figure.jpg Our Insights - Weighing Efficacy vs. Tolerability: Lenvima + Keytruda in Advanced ccRCC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/2386364f-1ab7-49cb-a9d5-9bf702958b01/Final+Key+Lyn+jpeg.jpg Our Insights - Weighing Efficacy vs. Tolerability: Lenvima + Keytruda in Advanced ccRCC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/8745a048-8de1-4ebc-85cf-a1e9b43d1147/Cabo-and-Opdivo-Figure.jpg Our Insights - Weighing Efficacy vs. Tolerability: Lenvima + Keytruda in Advanced ccRCC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/rybrevant-and-exkivity-two-highly-innovative-new-therapies-to-treat-egfr-exon-20-insertion-positive-mnsclc monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/6b44bcf0-5798-48d6-a980-4d003b40d1db/amivantamab+figure+jpeg.jpg Our Insights - Rybrevant and Exkivity: two highly innovative new therapies to treat EGFR Exon 20 Insertion positive mNSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/prioritizing-indications-an-analytical-framework monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/b7ffc126-40d8-413c-86bd-b78fa5cadd40/Capture3.JPG Our Insights - Prioritizing Indications: An Analytical Framework - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/00c91122-2895-43e2-ae58-a3391ea6759c/Capture4.jpg Our Insights - Prioritizing Indications: An Analytical Framework - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/trodelvy monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1620308089728-0A9ZVCIO3QTMD7BHWGBJ/drivers.png Our Insights - Trodelvy: A New Option for Later Lines TNBC https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1620308186036-GK1C0FI62W5C04AL95OA/bubble+chart.png Our Insights - Trodelvy: A New Option for Later Lines TNBC Green bubbles represent drugs with a clinical innovation score greater than 10% (highly innovative drugs) Yellow bubbles represent drugs with a clinical innovation score of 5-10% (moderately innovative drugs) Orange bubbles represent drugs with a clinical innovation score of less than 5% (low innovation drugs) https://www.equinox-group.com/our-take-blog/monjuvi monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1602858415786-B5FG8S962GJE8G5V845V/Onco+Drivers.PNG Our Insights - Monjuvi: Newest Blockbuster in Relapsed/Refractory DLBCL https://www.equinox-group.com/our-take-blog/rozlytrek monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1598444849458-PHTY29O9KT7BKINNX65Q/Two+indications.PNG Our Insights - Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1598445081902-TFHMINPZGGVNDVP9DZNW/Writ+large+drivers.PNG Our Insights - Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1598445626818-156KZB09K8MR6FPOUB6G/brain+mets+drivers.PNG Our Insights - Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study https://www.equinox-group.com/our-take-blog/braf-melanoma monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1595345332905-7N02WD9P1SI1T6WDH2U5/Drivers.JPG Our Insights - Pfizer Combo Gains an Edge in BRAF+ Melanoma https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1595345364656-62KRQ4ZOVTQ96ZAJACO9/CvB.JPG Our Insights - Pfizer Combo Gains an Edge in BRAF+ Melanoma https://www.equinox-group.com/our-take-blog/trikafta-a-major-step-forward-for-cystic-fibrosis-patients monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1594821759112-62CD38C5VHUM6OFSGLR8/Drivers.JPG Our Insights - Trikafta: A Major Step Forward for Cystic Fibrosis Patients https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/37d88716-c4cd-4518-ade4-72c869cdf762/Screenshot+2026-10-06+154609.png Our Insights - Trikafta: A Major Step Forward for Cystic Fibrosis Patients https://www.equinox-group.com/our-take-blog/nicerecommendations monthly 0.5 2026-07-16 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1591108253996-ZJT8SE2WZUFP2D5Z87SE/2x2.png Our Insights - A Reliable Predictor of NICE Recommendation Note: “Innovative” means 5% or higher on Equinox Group’s Clinical Innovation metric https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1591198937774-FVM3ZYGVNIIEZ8AG610Y/bar+chart+corrected.jpg Our Insights - A Reliable Predictor of NICE Recommendation https://www.equinox-group.com/our-take-blog/brukinsa-shooting-behind-the-duck-in-rr-mantle-cell-lymphoma monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/30bc73b5-73c1-4b62-99bc-f104cd54e516/Brukinsa.png Our Insights - Brukinsa: Shooting behind the duck in R/R mantle cell lymphoma https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1590591750039-VTLPTREB4BTF93UYLMVL/image-asset.png Our Insights - Brukinsa: Shooting behind the duck in R/R mantle cell lymphoma https://www.equinox-group.com/our-take-blog/lynparza monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1588602598572-6SUQILMF1W6CGS61SMBA/Drivers+website.JPG Our Insights - Lynparza: Expanding into Prostate Cancer https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1588602635716-SGFI2W37M2UMFAIGL06I/CvB.JPG Our Insights - Lynparza: Expanding into Prostate Cancer https://www.equinox-group.com/our-take-blog/keytruda monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1585841024555-SOSGU5CEWSRAAQW1XKX1/Bubble+chart.JPG Our Insights - Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda has described https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1585841143960-ARE7L77TWA5LJFRFMDFN/CvB+without+Keytruda+and+arrows.jpg Our Insights - Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1585843138108-26S1BH4W3NQD7E85H1N5/CvB+with+Keytruda.JPG Our Insights - Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda https://www.equinox-group.com/our-take-blog/enhertu monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1585241189071-9BAAYDVD4DJGHN8FIUUA/drivers+correct.JPG Our Insights - Enhertu: A New Leader in Later-Line Breast Cancer https://www.equinox-group.com/our-take-blog/parp-inhibitors-promise-in-new-maintenance-indications monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1603990710691-JHS4N4Z5ZNDXC5WFDVYI/Zejula+Updated.JPG Our Insights - PARP Inhibitors: Promise in New Maintenance Indications https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1603990728831-UXFULKXF6TXN3K4CJP8A/Lynparza+updated.JPG Our Insights - PARP Inhibitors: Promise in New Maintenance Indications https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1583425531368-327EG3JH72LVHS7KU2IM/CvB+CORRECT.JPG Our Insights - PARP Inhibitors: Promise in New Maintenance Indications https://www.equinox-group.com/our-take-blog/candidate-observations-to-be-added-to-equinoxs-oncology-normative-pricing-model monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/b54d2a73-d094-4b3f-8df2-11b910b891c7/now+onco.png Our Insights - Candidate Observations to Be Added to Equinox’s Oncology Normative Pricing Model Pale dots: original observation set Green dots: new candidate observations https://www.equinox-group.com/our-take-blog/tecentriq-and-imfinzi-both-offer-modest-improvements-in-sclc monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1571749786074-S0UBNJ51A4HMVUSHZ4OV/Capture.JPG Our Insights - Tecentriq and Imfinzi Both Offer Modest Improvements in SCLC https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1571750028542-6L0X1JDZT3JMWSM6ET4W/CvB.png Our Insights - Tecentriq and Imfinzi Both Offer Modest Improvements in SCLC https://www.equinox-group.com/our-take-blog/calquence-the-price-is-right monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1560888869487-KXDKYY85JDFGPR7247UW/Drivers+for+Calquence.PNG Our Insights - Calquence: The price is right https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1560890780544-18RUQQ0FPBVZUW5RPORG/Calquence.jpg Our Insights - Calquence: The price is right https://www.equinox-group.com/our-take-blog/radicava monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/36320093-d85b-4a48-8559-7184c145a00c/Screenshot+2025-08-06+090503.png Our Insights - Radicava: Not Innovative Enough to Sustain Strong Start - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.equinox-group.com/our-take-blog/how-to-price-an-oncology-drug monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1559761834460-NV589J7GQGTCD75693R1/dfsdf.png Our Insights - How to Price an Oncology Drug A new drug’s proposed cost (on Y-axis, inverted scale) should align with its promised clinical benefit (on X-axis) to place it in the “cloud” of successful recent launches. https://www.equinox-group.com/our-take-blog/hemlibra monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1553864002874-LGZVPJLBXZV76I6ZLB5Z/Capture.JPG Our Insights - Hemlibra: A Strong Leader in Hemophilia A https://www.equinox-group.com/our-take-blog/oral-semaglutide-a-game-changer-in-type-2-diabetes monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1551973852975-I1VKSO7P74C4HR59WCKG/Capture.JPG Our Insights - Oral semaglutide: A game changer in type 2 diabetes https://www.equinox-group.com/our-take-blog/tymlos-a-new-force-in-the-osteoporosis-market monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1549483554685-E9ARBRMVN1IDLMP2UEAZ/image-asset.jpeg Our Insights - Tymlos: A new force in the osteoporosis market https://www.equinox-group.com/our-take-blog/xeljanz-is-ulcerative-colitis-finally-the-place-for-jaks-to-shine monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1549483141877-TU1NO4EJZJ8VN5NKC0FH/Capture.JPG Our Insights - Xeljanz: Is ulcerative colitis finally the place for JAKs to shine? https://www.equinox-group.com/our-take-blog/imbruvica monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547482249237-ISADBOM7X8BLTSVKD5H5/imbruvica+1.JPG Our Insights - Imbruvica: Closing the window of opportunity in CLL https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547482533626-D39Z6T9GEDXG1MHIHSRT/Imbruvica+schema.png Our Insights - Imbruvica: Closing the window of opportunity in CLL This figure shows the domains of medical need in first line CLL. The gold bars reflect how well ibrutinib satisfies need in each domain. The grey area above the gold bar shows the extent of opportunity for improvement for developmental agents. We derive ibrutinib’s values by transforming clinical data to dimensionless index scores between 0 (no need―e.g., perfect efficacy) and 5 (no satisfaction of need―e.g., no efficacy). The transformation functions are consistent across indications, and domain analyses are built up from detailed sub-analyses. The interpretation for ibrutinib in CLL is that little opportunity remains for improving efficacy, convenience, mortality, or morbidity. The only remaining opportunity for meaningful improvement is in safety/tolerability. The high level of need in the cost domain is driven by high drug cost (which is warranted, given the magnitude of clinical benefit). https://www.equinox-group.com/our-take-blog/keytruda-exceptional-early-results-in-a-small-colorectal-cancer-population monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547486604530-JTLSZHYOQK1BF2GQO1UU/image-asset.jpeg Our Insights - Keytruda: Exceptional early results in a small colorectal cancer population https://www.equinox-group.com/our-take-blog/blincyto monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547486806942-QCO9VIJ9DCZER9EUKI9L/image-asset.jpeg Our Insights - Blincyto: High price for an undifferentiated drug https://www.equinox-group.com/our-take-blog/multiple-sclerosis monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547484722975-3HTUTL1DGAK7DSKNF9DU/MS+1.JPG Our Insights - Gilenya, Aubagio, and Tecfidera in Multiple Sclerosis https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547484761606-4VZ085BFORD5I5TBQ0FE/MS+2.JPG Our Insights - Gilenya, Aubagio, and Tecfidera in Multiple Sclerosis https://www.equinox-group.com/our-take-blog/pd-1-inhibitors monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547243356499-CVO19TOQ07C2OFN2T5Y3/opdivo+1.png Our Insights - PD-1 Inhibitors: Strong starts in three indications https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547243382771-FD41EG93E4NCD752JJMI/image-asset.png Our Insights - PD-1 Inhibitors: Strong starts in three indications https://www.equinox-group.com/our-take-blog/avastin monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547216717471-CJKDUEUU8WMKPIEQVSVR/avastin.png Our Insights - Avastin: One molecule in multiple cancers Note: Bubble size reflects size of the patient population https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547216882097-5U2225L8WZ5LDP0JTQUB/avastin+1.png Our Insights - Avastin: One molecule in multiple cancers https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547216928689-OD0V18COH2SAVYTVAUJC/avastin+2.png Our Insights - Avastin: One molecule in multiple cancers https://www.equinox-group.com/our-take-blog/jardiance monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547482116112-G22F5YRW4ORXZ264R9BS/jardiance.jpg Our Insights - Jardiance: New outcomes data in type 2 diabetes https://www.equinox-group.com/our-take-blog/kyprolis monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547487102982-R5CBCCSTNO04O5NFJ1YH/image-asset.jpeg Our Insights - Kyprolis: A rapid rise in a crowded market https://www.equinox-group.com/our-take-blog/brintellix-another-me-too-in-major-depression monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547483595212-ACM709QCGYHNFQTD8S90/image-asset.jpeg Our Insights - Brintellix: Another "me too" in major depression https://www.equinox-group.com/our-take-blog/pradaxa-stroke-prevention-in-atrial-fibrillation monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547485555815-564EMT00PBZFSJRZ1F17/image-asset.jpeg Our Insights - Pradaxa: Stroke prevention in atrial fibrillation https://www.equinox-group.com/our-take-blog/stelara-exceeding-expectations-in-psoriasis monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547485029228-4YGCTGOAAJT5LXDSNUH5/image-asset.jpeg Our Insights - Stelara: Exceeding expectations in psoriasis https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547485117506-HKKUYYBAA5HKLJYR85RN/image-asset.jpeg Our Insights - Stelara: Exceeding expectations in psoriasis https://www.equinox-group.com/our-take-blog/pristiq-no-innovation-in-major-depressive-disorder monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547486172010-ICQ64LPXUIQ0TE2F7CBC/image-asset.jpeg Our Insights - Pristiq: no innovation in major depressive disorder https://www.equinox-group.com/our-take-blog/benlysta monthly 0.5 2026-10-06 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1547483949927-F0HMGHS6WV3IIYV5YN8I/image-asset.jpeg Our Insights - Benlysta in SLE: A cautionary tale https://www.equinox-group.com/our-take-blog/category/Oncology monthly 0.5 https://www.equinox-group.com/our-take-blog/category/R%26D+Insights monthly 0.5 https://www.equinox-group.com/our-take-blog/category/Chronic+Disease monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/oveporexton monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Lenvima monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Indication+Prioritization monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/risperidone monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/PNH monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/keytr monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/oncology monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/empaveli monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Mektovi monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Repatha monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Casgevy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/TNBC monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Approval monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/CELMoD monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/ROS1 monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Carvykti monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/ovarian+cancer monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Alkermes monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Yescarta monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Alecensa monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Forecasting monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Hemophilia+A monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/emicizumab monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/RCC monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Xtandi monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Rybrevant monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Trikafta monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Zolgensma monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/pancreatic monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/roche monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Lyfgenia monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Chronic+Disease monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Vertex monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/DLBCL monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Amgen monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/ovarian monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Genetix+Biotherapeutics monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/edaravone monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/maintenance+therapy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Oncology monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Kite monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Disease+Area+Strategy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Xalkori monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Ovarian+Cancer monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Sunovion monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/soliris monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/2L monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Exkivity monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Small+molecule monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Sickle+cell+disease monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Hypertrophic+Cardiomyopathy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/radicava monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/cardiovascular+disease monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Xeljanz monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/NSCLC monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Hematology monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/alexion monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/novartis monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Opioid monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Brukinsa monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Eisai monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Unmet+Need monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Aduhelm monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Braftovi monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Novartis monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Keytruda monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/donanemab monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/MCL monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/NICE monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/pharma monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Gilead monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Journavx monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Lynparza monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Enhertu monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Platinum-Resistant+Ovarian+Cancer monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Brain+Mets monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Breyanzi monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Takeda monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/narcolepsy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/ALS monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Evrysdi monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/SMA+Type+1 monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/schizophrenia monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Xolair monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/piasky monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/hypercholesterolemia monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/fabhalta monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Camzyos monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Roche monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Lybalvi monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/ulcerative+colitis monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/AstraZeneca monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Zytiga monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Zejula monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Trodelvy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Multiple+Myeloma monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Primary+Market+Research monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Insights monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Melanoma monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/gene+therapy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/bezuclastinib monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/osteoporosis monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Oncol monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/J%26J monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/R%26D monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Chemotherapy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Genentech monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Pharmaceutical+Insights monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/TKI monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/HCM monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Advate monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Zegfrovy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Food+allergy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Monjuvi monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/rare+disease monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/ACTIVE monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/HRRm monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Eli+Lilly monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/BRCA-mutated monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Bristol+Myers+Squibb monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/riluzole monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Hemlibra monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Spinal+Muscular+Atrophy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Combination+therapy monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Merck monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/epidemiology monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Spinraza monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Planning+for+the+future monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Clinical+Innovation monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Janssen monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/MACE+prevention monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Tymlos monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/lenalidomide monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Myqorzo monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Cytokinetics monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/ultomiris monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/apellis monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Rozlytrek monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Cogent+Biosciences monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Lipfendra monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Incyte monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/GIST monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/PROTAC monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Pfizer monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/breast+cancer monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Daiichi-Sankyo monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Breast+Cancer monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/prostate+cancer monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Biogen monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Equinox monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/drug+pricing monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Alzheimer%27s+Disease monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/SCD monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Cystic+Fybrosis monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Mantle+Cell+Lymphoma monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/HER2%2B monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Acute+pain monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/Leqembi monthly 0.5 https://www.equinox-group.com/our-take-blog/tag/ulotaront monthly 0.5 https://www.equinox-group.com/about-us daily 0.75 2026-07-21 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/0f86d9c2-2bfd-4884-b402-44a3a0525758/unsplash-image-5Q07sS54D0Q.jpg About Us - Disease Area Strategy Click here to view our Disease Area Scan and Indication Prioritization Tools https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762461983655-ZW4QU8X6JA1ZGWOLI77K/unsplash-image-nApaSgkzaxg.jpg About Us - Business Development & Early R&D Click here to view our Disease Target Assessment Framework https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762462006896-P6RWDR5QIBSEVQ5JQN29/unsplash-image-Wb63zqJ5gnE.jpg About Us - Late-Stage Development Click here to view our tools to predict patient share, patient flow, and market access https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/b4d6d075-5d93-406c-9140-962ab4d20b93/unsplash-image-5fNmWej4tAA.jpg About Us - Our Unmet Need Framework Discover the framework at the heart of our analysis and how we use it to predict patient share https://www.equinox-group.com/home daily 1.0 2026-07-21 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/ba35d500-20aa-4e40-b1d0-2a0f20d53251/banner_insight_glow.png Home https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/c6f3544a-0429-48fa-9759-c13efc0a5a20/equinox-bg-development.jpg https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/cc2848c6-4fd6-4f7f-97bd-b13e8d4b3896/lifecycle-timeline+%283%29.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/fb4bc383-0824-438d-ba1b-0148e937716e/explore-arrow.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/df1ad3de-8fe1-4ba1-acd5-5293afe634b2/equinox-bg-bd-early-rd.jpg https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/fb4bc383-0824-438d-ba1b-0148e937716e/explore-arrow.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/98b81017-525d-419a-a023-65c6408fb0b7/equinox-bg-development.jpg https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/fb4bc383-0824-438d-ba1b-0148e937716e/explore-arrow.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/39810aea-df3a-47ef-b0a9-e4cf4baffa46/Screenshot+2026-07-16+194659.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/fb4bc383-0824-438d-ba1b-0148e937716e/explore-arrow.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/aefec638-b08f-4756-9a05-54ecd54ea7cf/Untitled+%2873%29.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/a04128a5-ea2e-44f0-84a9-2a96070d824b/arrow-right.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/7aff95ab-4186-4c9a-ad70-5cf2ab00d477/product%2Bx%2Bvs%2By%2Bdrivers.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/f41b1195-2edb-42c4-8b88-c81215ec51fe/arrow-down.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761925330284-924UGMWRNMD4PNQLGSZP/Screenshot+2025-10-31+114202.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/b41d77ce-5703-4e8f-bf44-ab565d4ee6e0/unsplash-image-5Q07sS54D0Q.jpg Home - Disease-Area Strategy Find out which indications offer the best commercial opportunities and how to prioritize them https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/af9098d0-7a94-4189-a706-4a1354b4cf02/unsplash-image-nApaSgkzaxg.jpg Home - Business Development & Early R&D Assess an asset's commercial potential, whether you're evaluating an in-licensing opportunity or developing a TPP https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/a874c24d-bedd-4aa3-bf19-072ff974e020/unsplash-image-Wb63zqJ5gnE.jpg Home - Late-Stage Development Dive into our patient-share forecasting, patient-flow modeling, and market access tools https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/d03e154d-e3ec-40c6-ade5-322f2a8dd06d/unsplash-image-5fNmWej4tAA.jpg Home - The Unmet Need Framework Discover the framework at the heart of our analysis and how we use it to predict patient share https://www.equinox-group.com/how-it-works daily 0.75 2026-07-21 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/f87c9041-82ea-4cff-8176-c75ba72bc6ce/Factors+we+assess.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/0c64df89-8be6-4387-a4c9-8bf62391f167/market_matrix_table.jpg https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/f87c9041-82ea-4cff-8176-c75ba72bc6ce/Factors+we+assess.png How It Works - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/0c64df89-8be6-4387-a4c9-8bf62391f167/market_matrix_table.jpg How It Works - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/3e9f6ff7-7a9f-4e43-a7ac-9afd4b93c2b3/1c-oncology-share+%281%29.png How It Works - Our Insights Read our published assessments of developmental agents and how we believe they will compete in the market https://video.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/3e166ecc-4374-4fe1-bec5-d8dfeb2f0abb/playlist.m3u8 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/0d62985f-20f2-4b71-905d-64192b519c14/Screenshot+2025-09-12+105914.png How It Works How It Works https://video.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/3e166ecc-4374-4fe1-bec5-d8dfeb2f0abb/playlist.m3u8 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/0d62985f-20f2-4b71-905d-64192b519c14/Screenshot+2025-09-12+105914.png How It Works How It Works https://www.equinox-group.com/contact daily 0.75 2026-07-20 https://www.equinox-group.com/what-our-staff-has-to-say daily 0.75 2026-07-17 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1754662232999-38I6L9L33BDPJ4M63TH1/unsplash-image-fVUl6kzIvLg.jpg What Our Staff Has to Say https://www.equinox-group.com/career-opportunities daily 0.75 2026-07-17 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1769208020893-ZEEWN6ZGCWYO3J5ZWZCG/unsplash-image-OQMZwNd3ThU.jpg Career Opportunities https://www.equinox-group.com/our-leadership daily 0.75 2026-07-21 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/92a4b330-e637-4d56-ab60-2889c02a018f/AMiller.jpg https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/f76f5064-3ae4-43d1-8fab-b82187155cde/Image.jpg https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1545163822353-ALL3IT5B615SCMN3T08R/KC_headshot.jpg https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1545163688392-I8VQ7IUVIX4RGWASW6U4/DAG%252Bwebsite.jpg https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/7c728c70-a1f1-4007-b9fe-7553e404bfeb/walt.jpg https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/92a4b330-e637-4d56-ab60-2889c02a018f/AMiller.jpg Our Leadership - Allan Miller Allan Miller is a Partner at Equinox Group. He received an M.A. and a Ph.D. in Molecular Biology from the University of Cambridge. His focuses are oncology, virology, and patient flow modeling techniques. https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/f76f5064-3ae4-43d1-8fab-b82187155cde/Image.jpg Our Leadership - Jack Lindberg Jack Lindberg is a Partner at Equinox Group. He received a B.S. in Business Economics from Bentley University and an M.S. in Pharmaceutical Economics and Policy from MCPHS University. His focuses are unmet medical need analysis, R&D decision support, and competitive dynamics. https://www.equinox-group.com/privacy-policy daily 0.75 2026-07-16 https://www.equinox-group.com/schedule-a-meeting daily 0.75 2026-07-21 https://www.equinox-group.com/late-stage daily 0.75 2026-07-21 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/93ea6611-e30d-4a68-a314-e14e6eef430e/Share.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/3956463a-935c-49aa-a13d-4bcc83c8f587/Screenshot+2026-09-24+105827.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1772548625504-RKXS3ISHBJ9H2WB8RNJ2/Screenshot+2026-03-02+172059.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1783706105689-YA03R8ALWJEMF27557NY/Screenshot%2B2026-07-10%2B134826.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1783705950633-1SZP12A6AQRSKQNHYZU2/Screenshot+2026-07-10+135201.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762458560814-ISECEXRHF29ZF1J0CX6T/Screenshot+2025-11-05+085356.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762458851468-L60IMCV5EX2XE4PRAV3H/Specialized%2BTools%2B-%2BRare%2BDisease.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762458580462-SCTMIJ4P6LV2RXWDUCVI/Keytruda+CvB.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/c2295a75-cb1b-4df7-8cfe-4b927e0f7720/Screenshot+2026-09-23+141228.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/6c8342bc-687b-407e-b90a-251b32416ed6/2a-unmet-need-columns+%285%29.png Late Stage Development - Click Here to find out how it works https://www.equinox-group.com/bd-early-rd daily 0.75 2026-07-21 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761934668881-CPCRTSUBBAZCAJM5J5N3/UMN.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761925675720-K3F4HTS55L26G21A5V04/product%2Bx%2Bvs%2By%2Bdrivers.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761925330284-924UGMWRNMD4PNQLGSZP/Screenshot+2025-10-31+114202.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762458560814-ISECEXRHF29ZF1J0CX6T/Screenshot+2025-11-05+085356.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762458851468-L60IMCV5EX2XE4PRAV3H/Specialized%2BTools%2B-%2BRare%2BDisease.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1762458580462-SCTMIJ4P6LV2RXWDUCVI/Keytruda+CvB.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/c2295a75-cb1b-4df7-8cfe-4b927e0f7720/Screenshot+2026-09-23+141228.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/6c8342bc-687b-407e-b90a-251b32416ed6/2a-unmet-need-columns+%285%29.png BD & Early R&D - Click Here to find out how it works https://www.equinox-group.com/disease-area-strategy daily 0.75 2026-07-21 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761922460286-ATGBP6DPZH62TIDY60FD/indication+prior+CI+UMN+website.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1770646868104-G6QQT07U4QMGD035PFA2/heat+map+for+website.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761922613809-ANISX12XO3ED8GHX4IY0/Screenshot%2B2025-10-31%2B105128.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1761925675720-K3F4HTS55L26G21A5V04/product%2Bx%2Bvs%2By%2Bdrivers.png https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/c2295a75-cb1b-4df7-8cfe-4b927e0f7720/Screenshot+2026-09-23+141228.png https://www.equinox-group.com/tools daily 0.75 2026-07-17 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1fe91be7-5f46-4dda-8507-2e7138bd3b6e/equinox-bg-strategy.jpg https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/6e69b4d1-c71e-49ed-bd31-77bad38d7e90/equinox-bg-bd-early-rd.jpg https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/71d17336-5419-4609-a75f-6ad1128dabd2/equinox-bg-development.jpg https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/42cb6707-cdc4-41a0-845b-f7faa4921f8d/unsplash-image-5Q07sS54D0Q.jpg Our Tools - Disease Area Strategy Click here to view our Disease Area Scan and Indication Prioritization Tools https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/72bff55f-faf2-47b5-82da-203f6e1e2215/unsplash-image-nApaSgkzaxg.jpg Our Tools - Business Development & Early R&D Click here to view our Disease Target Assessment Framework https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/b30a8af7-3c30-4f47-8e0b-711d5cd902db/unsplash-image-Wb63zqJ5gnE.jpg Our Tools - Late-Stage Development Click here to view our Competition Module tools to predict patient share, patient flow, and market access https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/6c8342bc-687b-407e-b90a-251b32416ed6/2a-unmet-need-columns+%285%29.png Our Tools - The Unmet Need Framework Click Here to find out how it all works https://www.equinox-group.com/what-on-earth-is-clinical-innovation daily 0.75 2026-07-21 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1fe91be7-5f46-4dda-8507-2e7138bd3b6e/equinox-bg-strategy.jpg https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/6e69b4d1-c71e-49ed-bd31-77bad38d7e90/equinox-bg-bd-early-rd.jpg https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/71d17336-5419-4609-a75f-6ad1128dabd2/equinox-bg-development.jpg https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/0f86d9c2-2bfd-4884-b402-44a3a0525758/unsplash-image-5Q07sS54D0Q.jpg What on earth is Clinical Innovation? - Disease Area Strategy Disease Area Strategy Click here to view our Disease Area Scan and Indication Prioritization Tools https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1763671858133-6NRLW0ALTCGRIFRGHAAO/unsplash-image-nApaSgkzaxg.jpg What on earth is Clinical Innovation? - Early R&D Early R&D https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/1763671831309-WZC8HLQLNMQ90FD7940B/unsplash-image-Wb63zqJ5gnE.jpg What on earth is Clinical Innovation? - Late-Stage Development Click here to view our Competition Module tools to predict patient share, patient flow, and market access https://video.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/3e166ecc-4374-4fe1-bec5-d8dfeb2f0abb/playlist.m3u8 https://images.squarespace-cdn.com/content/v1/5c19207d5ffd20ca69911301/62dc03da-5780-4869-88da-771d13166188/CI+Slide+2.png What on earth is Clinical Innovation? https://www.equinox-group.com/quote daily 0.75 2026-07-20